Is QuidelOrtho profitable in 2026?

No. QuidelOrtho posted a Q1 2026 net loss of $91.8M and a GAAP diluted loss per share of $1.35, with adjusted EPS also negative at $0.04, per its May 5, 2026 earnings release, despite full-year 2025 adjusted EBITDA of $597M.

Is QuidelOrtho laying off workers?

Headcount fell modestly to about 6,500 employees as of December 28, 2025, down roughly 1.5% year over year, as the company banked $140M in annualized cost savings by end of 2025 rather than announcing large-scale layoffs.

Could AI replace QuidelOrtho's diagnostics business?

Unlikely for its core: FDA-cleared hardware and reagent assays across ~145,000 installed instruments (per company reporting, 2026) are regulated, liability-bearing physical products AI software cannot replicate, though peripheral informatics/result-flagging tools are more exposed to automation.

Is QuidelOrtho selling its Point of Care business?

As of June 29, 2026, QuidelOrtho was reportedly in talks to sell its entire Point of Care testing unit to private equity buyers for roughly $1.5B, news that sent QDEL shares up 35% that day.

Who owns QuidelOrtho?

QuidelOrtho is an independent public company (Nasdaq: QDEL) with no parent, formed in 2022 through the merger of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc; market cap was about $1.13B as of July 24, 2026.

Biotech tools companies · United States

QuidelOrtho Corporation

quidelortho.com ↗

Diagnostics maker selling lab instruments and the test cartridges/reagents that run on them.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from August 6, 2026 · Every call on the record Checkpoint: Q2 2026 earnings and update on Point-of-Care unit sale closing

The call

The installed base still locks in recurring buyers, but debt, cash burn, and a shrinking Point-of-Care business are the bigger threat, not any rival's product launch.

QuidelOrtho sells machines that test blood and heart markers to hospitals and labs, plus the test supplies those machines use over time. It has locked-in customers (145,000 machines in hospitals that keep buying supplies), which is hard for rivals like Abbott and Roche to steal, but the company owes so much money ($2.87 billion in debt versus only $1.13 billion in market value) that it is losing cash every quarter and cannot invest in new products or buy competitors. The one thing that could save it is if selling off some of its business brings in enough cash to pay down debt and stop the bleeding, which should become clear by late summer 2026.

Why

AI pressure: None apparent. This is hardware and reagent chemistry, not software; no AI lab or agent currently displaces instrument placements or assay contracts. Could AI do the core job? Unlikely.

Bigger players: Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher (Beckman Coulter, Cepheid). All four already sell competing instrument and consumable lines into the same hospitals and labs, with far larger balance sheets to fund price wars. Could a giant copy it? Yes, easily.

What protects it. About 145,000 installed instruments and 95-97% recurring consumable revenue make switching labs to a rival costly and slow.

What would change this call

Q2 2026 earnings release on August 6, 2026 versus revised FY2026 guidance. Shows whether Point-of-Care and overall revenue erosion is stabilizing or worsening.
Closure of the Point-of-Care unit sale at the reported ~$1.5B valuation. Shows whether QuidelOrtho can exit the segment losing share and use proceeds to cut its $2.87B debt.
Free cash flow turning positive in Q3 or Q4 2026 after the reported negative $159M TTM figure. Shows whether cash burn from competitive and debt pressure is easing or forcing refinancing risk.

Key numbers

Net debt about 4.2x EBITDA against $1.13B market cap (2026-02-11)
Q1 2026 revenue $620M, down 13% constant currency (2026-05-05)
FY2026 revenue guidance cut to $2.0-2.75B from $2.7-2.9B (2026-05-05)

Named risks

High leverage: net debt/EBITDA 4.2x and ~$2.87B debt vs $1.13B market cap (mid-2026). Severity: high
Negative trailing free cash flow of $159M signals ongoing cash burn. Severity: high
Point-of-Care segment revenue fell 34% in Q1 2026 amid weak respiratory season and China destocking. Severity: medium
Active securities-fraud class action and new law firm investigation over 2022-2024 statements. Severity: medium
Structural disadvantage against larger-scale Abbott, Roche, Siemens, Danaher in mature IVD market. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Abbott Laboratories	losing to	Q1 2026 revenue down 13% cc and POC down 34% vs larger-scale incumbent, 2026-05-05
F. Hoffmann-La Roche (Roche Diagnostics)	losing to	Characterized as second-tier IVD player behind Roche in market analyses, 2026
Siemens Healthineers	losing to	Outscaled amid QuidelOrtho's 4.2x leverage and cut FY2026 guidance, 2026-05-05
Danaher Corporation (Beckman Coulter, Cepheid)	contesting	Direct competition in immunoassay/molecular segments amid QuidelOrtho's Labs growth of 6%, FY2025

Questions people ask

Is QuidelOrtho profitable in 2026?: No. QuidelOrtho posted a Q1 2026 net loss of $91.8M and a GAAP diluted loss per share of $1.35, with adjusted EPS also negative at $0.04, per its May 5, 2026 earnings release, despite full-year 2025 adjusted EBITDA of $597M.
Is QuidelOrtho laying off workers?: Headcount fell modestly to about 6,500 employees as of December 28, 2025, down roughly 1.5% year over year, as the company banked $140M in annualized cost savings by end of 2025 rather than announcing large-scale layoffs.
Who is QuidelOrtho's biggest competitor?: QuidelOrtho is widely characterized as a second-tier IVD player behind Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Danaher (Beckman Coulter, Cepheid), all of which outscale it in diagnostics as of 2026.
Could AI replace QuidelOrtho's diagnostics business?: Unlikely for its core: FDA-cleared hardware and reagent assays across ~145,000 installed instruments (per company reporting, 2026) are regulated, liability-bearing physical products AI software cannot replicate, though peripheral informatics/result-flagging tools are more exposed to automation.
Is QuidelOrtho selling its Point of Care business?: As of June 29, 2026, QuidelOrtho was reportedly in talks to sell its entire Point of Care testing unit to private equity buyers for roughly $1.5B, news that sent QDEL shares up 35% that day.
Who owns QuidelOrtho?: QuidelOrtho is an independent public company (Nasdaq: QDEL) with no parent, formed in 2022 through the merger of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc; market cap was about $1.13B as of July 24, 2026.

Timeline

2026-07-23Kaskela Law Firm announces investigation into alleged misleading statements from 2022-2024
2026-06-29Point-of-Care unit sale talks valued at ~$1.5B reported; QDEL shares jump 35%
2026-06-23Micah Young appointed CFO, succeeding retiring CFO Joseph Busky
2026-05-05Q1 2026 results: revenue $620M down 13% cc, net loss $91.8M, FY2026 guidance cut
2026-04-20Completes acquisition of LEX Diagnostics for ~$100M cash
2026-02-11FY2025 results: revenue $2.73B, adjusted EBITDA $597M, 22% margin
2025-10-31VITROS high-sensitivity Troponin I assay receives FDA 510(k) clearance
2024-04-12Bristol County Retirement securities-fraud class action filed against QuidelOrtho
2022QuidelOrtho formed via merger of Quidel Corporation and Ortho Clinical Diagnostics

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation